Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of August 2019, with a specific reporting date of August 12, 2019. The document serves as a transaction notification under Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, detailing insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs).
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It exclusively reports on specific share acquisition transactions.
| Instrument | Transaction Type | Price per Share | Total Volume | Transaction Date | Exchange |
|---|---|---|---|---|---|
| Ordinary Shares (25p each) | Acquisition under Share Reward Plan | £16.7434 | 14 to 16 shares per individual | August 9, 2019 | London Stock Exchange (XLON) |
Material Changes
The filing does not contain comparative financial data or material changes to the company's business operations versus prior periods. It reports routine acquisitions of ordinary shares by executives under the Company's Share Reward Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of specific equity transactions.
Important Facts for Investors
- Insider Activity: Nine individuals, including CEO Emma Walmsley and President of Global Vaccines Richard Connor, acquired shares on August 9, 2019.
- Transaction Nature: All transactions were acquisitions of Ordinary Shares under the Company's Share Reward Plan, consisting of partnership shares and matching shares.
- Transaction Volume: Most executives acquired 14 shares (7 partnership + 7 matching), while President of Global Affairs Peter Thomson acquired 16 shares (8 partnership + 8 matching).
- Share Price: The execution price for all transactions was £16.7434 per share.
- Financial Data Absence: This document does not contain GSK's financial performance results; investors should refer to Form 20-F or quarterly earnings releases for revenue and profit data.